Get the MDVN Research Report and
Also Receive Our Top Trades for 2017!

Medivation, Inc.

On June 16th, Medivation announced results from a Phase I/II study of pidilizumab, an investigational antibody with immune-mediated anti-tumor effects, that demonstrated potential clinical benefit in pediatric patients with diffuse intrinsic pontine glioma (DIPG). The study, which was exploratory in nature, was designed to assess the safety and tolerability of pidilizumab, as well as key clinical outcomes, such as event-free and overall survival, in this pediatric population. On June 2nd, Mediva … (See Research Report)
Download Research Report
on MDVN Now